Aldevron has announced its expansion plans for its Freiburg, Germany facility. The Freiburg location houses the GENOVAC antibody development platform and became the second site for Aldevron in 2004. Founding partner and chief executive officer, Michael Chambers, cites the need for space and capacity to support the company’s steady growth in providing world class genetic immunization strategies with high-quality antibody generation to customers across the globe as the major reason. “We have s...